Novartis AG

2 days ago · seekingalpha.com

Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected pipeline revenue may support growth over the longer term. NVS trades at a discount to peers on forward P/E but at a premium on EV/EBITDA, producing mixed relative valuation signals.

2 days ago · zacks.com

Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 days ago · zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 days ago · cnbc.com

Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a late-stage clinical trial for patients with relapsing multiple sclerosis, while reaching its primary endpoint, appeared worse than expected.

4 days ago · seekingalpha.com

Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas, Research Division Michael Leuchten - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Urban Fritsche - Zürcher Kantonalbank, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Presentation Isabella Zinck Investor Relations Manager Hi, everyone, and welcome to our Q3 earnings call.

5 days ago · marketbeat.com

Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.

5 days ago · zacks.com

Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.

5 days ago · benzinga.com

Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the timeline shifting due to additional clinical work to be completed.

5 days ago · zacks.com

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

5 days ago · investors.com

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.